A5045891981- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- BRCA gene mutations in cancer
- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Breast Implant and Reconstruction
- Estrogen and related hormone effects
- PARP inhibition in cancer therapy
- Uterine Myomas and Treatments
- Cancer Risks and Factors
- Lung Cancer Treatments and Mutations
- Metastasis and carcinoma case studies
- Cancer survivorship and care
- Genetic factors in colorectal cancer
- Neutropenia and Cancer Infections
- Cancer Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Endometriosis Research and Treatment
- Global Cancer Incidence and Screening
- Lung Cancer Research Studies
University Hospital Ulm
2016-2025
Universität Ulm
2015-2024
Universitäts Frauenklinik
2015-2024
Olgahospital
2008-2024
Klinik für Frauenheilkunde
2015-2024
Institut für Frauengesundheit
2024
Universitätsklinikum Tübingen
2024
Ernst Abbe University of Applied Sciences Jena
2023
Applied Science University
2023
University and Rehabilitation Clinics Ulm
2016-2022
The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) negative human epidermal growth factor 2 (HER2).In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy safety selective CDK4/6 inhibitor ribociclib combined with letrozole first-line treatment 668 postmenopausal women HR-positive, HER2-negative recurrent metastatic who had...
We assessed the prognostic significance of presence micrometastasis in bone marrow at time diagnosis breast cancer by means a pooled analysis.
Abstract Purpose: The CellSearch system (Veridex, Warren, NJ) is designed to enrich and enumerate circulating tumor cells (CTCs) from peripheral blood. Here, we validated the analytic performance of this for clinical use in patients with metastatic breast cancer. Experimental Design: This prospective multicenter study conducted at three independent laboratories involved samples 92 Intra- inter-assay variability using controls containing defined numbers (average, 50 1,000, respectively), cell...
Cytokeratins are specific markers of epithelial cancer cells in bone marrow. We assessed the influence cytokeratin-positive micrometastases marrow on prognosis women with breast cancer.
Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing patients. We assessed frequency mutations 17 predisposition genes, including BRCA1 and BRCA2, a large cohort patients with triple-negative (TNBC) unselected family history or ovarian determine utility those TNBC. Patients Methods TNBC (N = 1,824) were recruited through 12 studies, was sequenced identify mutations. Results Deleterious identified 14.6%...
Circulating tumor cells (CTCs) have been shown to predict reduced survival outcomes in metastatic breast cancer.CTCs were analyzed 2026 patients with early cancer before adjuvant chemotherapy and 1492 after using the CellSearch System. After immuno-magnetic enrichment for expressing epithelial-cell adhesion molecule, CTCs defined as nucleated cytokeratin lacking CD45. The followed a median of 35 months (range = 0-54). Kaplan-Meier analyses log-rank test used analyses. All statistical tests...
In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer. Whether overall would also be was not known.Here we report the results protocol-specified final survival, key secondary end point. Patients were randomly assigned 1:1 ratio to receive either or placebo...
Abstract Introduction MicroRNAs (miRs) are interesting new diagnostic targets that may provide important insights into the molecular pathogenesis of breast cancer. Here we evaluated, for first time, feasibility and clinical utility circulating miRs as biomarkers detection staging Methods The relative concentrations cancer-associated miR10b, miR34a, miR141 miR155 were measured in blood serum 89 patients with primary cancer (M0, n = 59) metastatic disease (M1, 30), 29 healthy women by a TaqMan...
Although unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTC) in peripheral blood patients with metastatic breast cancer, less is available for CTCs at time primary diagnosis.We conducted a pooled analysis individual data from 3,173 nonmetastatic (stage I-III) cancer five institutions. The prevalence and numbers were assessed diagnosis FDA-cleared CellSearch System (Janssen Diagnostics, LLC). Patient outcomes analyzed using meta-analytic procedures,...
The prognostic significance of disseminated tumor cells (DTC) in bone marrow (BM) breast cancer patients at the time primary diagnosis has been confirmed by a large pooled analysis. In view lack early indicators for secondary adjuvant treatment, we here evaluated whether persistence DTCs after therapy increases risk subsequent relapse and death.Individual patient data from 676 women with stages I-III 3 follow-up studies were pooled. During clinical follow-up, underwent BM aspiration (BMA) to...
As the available information about breast cancer is growing every day, decision-making process for therapy getting more complex. ChatGPT as a transformer-based language model possesses ability to write scientific articles and pass medical exams. But it able support multidisciplinary tumor board (MDT) in planning of patients with cancer?
Abstract Background The phenotypes of tumor cells change during disease progression, but invasive rebiopsies metastatic lesions are not always feasible. Here we aimed to determine whether initially HER2-negative breast cancer (MBC) patients with HER2-positive circulating (CTCs) benefit from a HER2-targeted therapy. Methods open-label, interventional randomized phase III clinical trial (EudraCT Number 2010-024238-46, CliniclTrials.gov Identifier: NCT01619111) recruited March 2012 until...
PURPOSE: There is an urgent need for markers that can predict the efficacy of adjuvant chemotherapy in patients with solid tumors. This study was designed to evaluate whether monitoring micrometastases bone marrow response systemic breast cancer. PATIENTS AND METHODS: Bone aspirates 59 newly diagnosed cancer either inflammatory (n = 23) or advanced (> four nodes involved) disease 36) were examined immunocytochemically monoclonal anticytokeratin (CK) antibody A45-B/B3 (murine...
Abstract Numerous single‐institutional studies and a large pooled analysis have demonstrated that the presence of disseminated tumor cells (DTCs) in bone marrow (BM) from patients with primary, nonmetastatic breast cancer (Stages I‐III) is associated impaired prognosis. To date, sampling BM assessment DTCs not considered routine procedure clinical management patients; however, emerging data suggest future role for risk stratification monitoring therapeutic efficacy. Because these options...